Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00127881
Status:
TERMINATED
Last Update Posted:
2012-07-26
First Post:
2005-08-08
Brief Title:
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Sponsor:
Emergent Product Development Seattle LLC
Organization:
Emergent Product Development Seattle LLC
Study Overview
Official Title:
Open Label Dose Escalation Followed by Open LabelSingle Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL Stage IB-IVB or Sezary Syndrome Who Are Refractory or Intolerant to Targretin Bexarotene and One Other Standard Therapy
Status:
TERMINATED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
New sponsor other treatments available
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the efficacy of the drug HuMax-CD4 in patients with mycosis fungoidesMF and sezary syndrome who are intolerant to or do not respond to treatment with Targretin and one other standard therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None